Category Archives: Central and Eastern Europe
The World’s First VisONE® Implantation: a promising start
Below, we are re-publishing with permission the press-release issued by the Heart Institute on the 28th of September 2018 “Thanks to the efforts of the study team from the Heart Institute, we have conducted the first worldwide implantation of the VisONE … Continue reading
Clinical Accelerator announces collaboration with Oncolix for developing Prolanta™, a targeted therapeutic protein for the treatment of ovarian, breast and other cancers
Clinical Accelerator, a full-service contract research organization, is pleased to announce that it has entered into a collaboration with Oncolix, for conducting clinical studies for its analogue protein, Prolanta, to treat ovarian cancer. The trials will be conducted in the … Continue reading
VisCardia Announces First Implant of the VisONE® System for Treating Heart Failure
Below, we are re-publishing with permission the press-release issued by VisCardia Inc. on the 1st of August 2018 PORTLAND, Ore.–VisCardia Inc., a privately held medical device developer, announced today the first implant of the VisONE® implantable system for heart failure, and … Continue reading
FDA inspections produce solid evidence of high quality clinical trial data originating in Central and Eastern Europe
Clinical Accelerator is a clinical CRO with a special focus on Central and Eastern Europe currently operating in 11 countries of that region: Bulgaria, Estonia, Georgia, Hungary, Latvia, Lithuania, Moldova, Poland, Romania, Russian Federation, and the Ukraine (listed alphabetically). The … Continue reading
ARREST Phase IIb Top-Line 52 weeks results
Below, we are re-publishing with permission the press-release issued by Galmed Pharmaceuticals Ltd. on the 12th of June 2018 Galmed’s 600 mg Aramchol™ Achieved a Regulatory Approvable Endpoint Showing NASH Resolution Without Worsening of Fibrosis, in NASH Patients, in the Global … Continue reading
Replicor discloses long term functional control of HBV and HDV infection in high proportions of treated patients at EASL 2018
Below, we are re-publishing with permission the press-release issued by Replicor on the 13th of April 2018 MONTREAL, April 13, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic … Continue reading
Clinical Accelerator announces collaboration with VisCardia for investigating a novel device therapy for chronic heart failure
Kiev, Ukraine – December 11, 2017: Clinical Accelerator, a full-service clinical contract research organization, is pleased to announce it has entered into a collaboration with VisCardia Inc. for conducting clinical studies for its VisONE medical device in the Ukraine. The … Continue reading
Promising Interim Clinical Data for NOX66
Below, we are re-publishing with permission the press-release issued by Noxopharm Limited on the 20th of November 2017 PROMISING INTERIM CLINICAL DATA FOR NOX66 Patients with metastatic, late-stage cancers 10 of 11 patients showing no disease progression following 3-months treatment with NOX66 … Continue reading
REPLICOR’S NEW PHASE II TRIAL CONDUCTED BY CLINICAL ACCELERATOR PRODUCES EXCITING CLINICAL DATA FOR THEIR NUCLEIC ACID POLYMER (NAP) DRUG REP 2139-CA FOR PATIENTS WITH HBV / HDV CO-INFECTION.
In December last year a Clinical Accelerator post (1) reported that recruitment was underway in Moldova for an interesting Phase II trial of Replicor’s novel nucleic acid polymer (NAP), REP 2139-Ca, in combination with the immunotherapeutic agent, pegylated interferon alfa-2a … Continue reading
IQPC finally recognizes the value of Eastern Europe for clinical trials
You don’t say! Packed with eager, treatment naive participants, and short of the many transportation complexities faced in little established research sites, Eastern Europe is becoming increasingly recognised as among the best places to conduct a clinical trial. The surprise … Continue reading
Posted in Central and Eastern Europe
Leave a comment
